Molecular analysis of antigen presentation machinery in circulating tumor cells from renal cell carcinoma and prostate cancer

Joshua M Lang1,3*, Jacob T Tokar2, Jamie Sperger1, Benjamin P Casavant2, Scott M Berry2, Lindsay N Strotman2, David J Beebe2,3

From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013

Aberrant expression of antigen presentation machinery (APM) has been closely associated with more aggressive tumors and may inhibit the therapeutic response to T-cell based immunotherapies. Furthermore, the selective pressure of immunotherapies may select for resistant clones that down regulate expression of APM as means of therapeutic resistance. This report characterizes a microfluidic assay for the screening and serial assessment of APM in circulating tumor cells (CTCs) from patients with advanced renal cell carcinoma and prostate cancer. Cell surface expression of MHC class I is identified in both renal cell and prostate cancer CTCs. Gene expression analysis for components of APM in CTCs is also validated using quantitative RT-PCR. The results of these studies suggest a unique CTC biomarker that may serve as a predictive and pharmacodynamic biomarker for use in clinical trials with T-cell based immunotherapies. Future studies will focus on the development of assays for markers of resistance to checkpoint inhibitors and expression of tumor associated antigens.

Authors’ details
1Department of Medicine, University of Wisconsin, Madison, WI, USA.
2Biomedical Engineering, University of Wisconsin, Madison, WI, USA.
3Carbone Cancer Center, University of Wisconsin, Madison, WI, USA.

Published: 7 November 2013

Submit your next manuscript to BioMed Central and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

© 2013 Lang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.